Celgene vs. Cipla: Consent Judgment in Pomalidomide Patent Dispute

Introduction

In a decisive outcome for pharmaceutical patent enforcement, Celgene Corporation secured a consent judgment and permanent injunction against Cipla Limited in the U.S. District Court for the District of New Jersey, blocking Cipla’s generic pomalidomide capsules from entering the U.S. market until expiration of three key patents. The case — filed February 10, 2025 and resolved September 17, 2025 in just 219 days — underscores the continued vitality of ANDA-based Hatch-Waxman litigation as a strategic enforcement mechanism for branded pharmaceutical companies.

At the heart of the dispute were U.S. Patent Nos. 8,828,427; 9,993,467; and 10,555,939, covering Celgene’s blockbuster multiple myeloma treatment Pomalyst® (pomalidomide). Cipla’s Abbreviated New Drug Application (ANDA No. 219718), seeking approval for generic pomalidomide capsules in 1 mg, 2 mg, 3 mg, and 4 mg strengths, triggered the litigation. The swift resolution through a stipulated consent judgment offers instructive lessons for patent holders, generic manufacturers, and R&D teams navigating pharmaceutical patent litigation.

Case Overview

The Parties

The Patents at Issue

Three patents were asserted in this action, forming a layered patent portfolio protecting Pomalyst® across its formulation and clinical application:

• • US 8,828,427 — covering formulation and/or treatment methods related to pomalidomide
• • US 9,993,467 — directed to therapeutic use and dosing regimens
• • US 10,555,939 — covering related pharmaceutical compositions or methods of treatment

The Accused Product

Cipla’s ANDA No. 219718 sought FDA approval for pomalidomide capsules in 1 mg, 2 mg, 3 mg, and 4 mg strengths — a direct generic equivalent to Pomalyst®. Filing a Paragraph IV certification against the listed patents triggered Celgene’s 45-day statutory window to file suit and activate a 30-month FDA approval stay under the Hatch-Waxman Act.

Legal Representation

• • Plaintiff Celgene: Saul Ewing LLP — Attorneys Alexander Lee Callo, Charles Michael Lizza, and Sarah Ann Sullivan
• • Defendant Cipla: K&L Gates LLP — Attorney Loly G. Tor

Both firms are experienced Hatch-Waxman litigators, reflecting the sophisticated, strategy-driven nature of pharmaceutical patent enforcement in the District of New Jersey.

Litigation Timeline & Procedural History

The case was filed in the U.S. District Court for the District of New Jersey — widely regarded as a premier forum for Hatch-Waxman pharmaceutical patent litigation given its experienced judiciary and established procedural frameworks for ANDA disputes.

The 219-day resolution is notably swift. Most contested Hatch-Waxman cases extend 18–36 months through claim construction, expert discovery, and trial. The parties’ agreement to a consent judgment here suggests that early case assessments, licensing discussions, or strategic commercial considerations drove a negotiated resolution well before trial — a pattern increasingly common in ANDA litigation when patent strength and infringement exposure are clearly defined.

The court retained jurisdiction for enforcement purposes, and the consent judgment was entered on September 11, 2025, with the case formally closed September 17, 2025.

The Verdict & Legal Analysis

Outcome

The court entered a Consent Judgment and Permanent Injunction by stipulation on September 11, 2025. No damages were awarded — consistent with Hatch-Waxman litigation convention, where the primary remedy is injunctive relief preventing pre-expiration generic market entry rather than monetary compensation.

Key injunctive terms:

• • Cipla is enjoined from making, using, selling, offering to sell, importing, or distributing its ANDA product in the United States until expiration of all three patents-in-suit
• • Injunction applies to Cipla’s successors and assigns
• • Celgene retains the right to authorize Cipla to market the product (enabling future licensing)

Notably, the consent judgment expressly preserves Cipla’s rights under 35 U.S.C. § 271(e)(1) (the Bolar exemption for research activities) and Paragraph IV certifications, and does not restrict the FDA from approving ANDA No. 219718. This means Cipla retains its approved ANDA and the legal ability to launch immediately upon patent expiration — a commercially significant carve-out.

Verdict Cause Analysis

This was a straightforward infringement action under the Hatch-Waxman framework. By filing a Paragraph IV certification asserting non-infringement or invalidity of the listed patents, Cipla created the statutory predicate for Celgene’s lawsuit. The consent judgment — with all claims and counterclaims dismissed with prejudice — indicates that no invalidity findings or non-infringement rulings were reached on the merits.

The absence of a validity challenge proceeding to judgment may reflect Cipla’s assessment that the asserted patents presented a difficult invalidity case, or that commercial considerations — including potential licensing arrangements not disclosed in the public record — made settlement preferable to protracted litigation.

Legal Significance

The Paragraph IV certification preservation clause (Paragraph 8 of the consent judgment) is strategically significant. It confirms that the settlement does not extinguish Cipla’s ability to challenge these patents in future proceedings or ANDA submissions — an increasingly standard provision that prevents consent judgments from operating as broad IP waivers.

The jurisdiction retention clause (Paragraph 6) ensures the District of New Jersey remains the enforcement forum for any future disputes regarding compliance — a standard but important mechanism for patent holders seeking efficient contempt remedies.

Strategic Takeaways

For Patent Holders:

• • Multi-patent portfolio strategies layering formulation, method-of-use, and dosing patents create durable Hatch-Waxman protection — as demonstrated here with three asserted patents across different application families.
• • Early consent judgment negotiations can preserve resources while securing equivalent injunctive relief to a full trial victory.

For Generic Manufacturers (ANDA Filers):

• • Preserving Paragraph IV certifications and Bolar exemption rights in consent judgments is essential — these provisions maintain the ability to launch at first expiration and conduct ongoing development.
• • ANDA approval is not restricted by the injunction, positioning Cipla for immediate commercial launch post-expiration.

For R&D Teams:

• • Freedom-to-operate (FTO) analyses must account for patent families covering not just core compounds but formulation variations, dosing regimens, and methods of treatment — all potential infringement vectors in ANDA litigation.

Industry & Competitive Implications

The Celgene v. Cipla outcome reflects broader dynamics in the branded pharmaceutical defense of specialty oncology drugs against generic competition. Pomalidomide, as a multiple myeloma treatment, occupies a high-value therapeutic category where patent protection timelines directly translate to billions in revenue.

The District of New Jersey’s status as the preeminent Hatch-Waxman litigation venue is reinforced by this filing. Companies in the pharmaceutical space should anticipate that layered patent portfolios — covering composition, formulation, method of use, and dosing — will continue to be the primary defensive strategy for branded manufacturers extending exclusivity beyond core compound patents.

For the generics industry, the outcome signals that early resolution via consent judgment remains a viable path when invalidity arguments are unlikely to overcome well-constructed patent portfolios. Cipla’s retention of its ANDA approval and Paragraph IV rights suggests a measured strategic retreat rather than full capitulation — preserving commercial options for future market entry.

The case also highlights the continuing importance of ANDA litigation monitoring for IP professionals and competitive intelligence teams tracking pharmaceutical market entry timelines.